Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors. (Q50694188)

17 March 2018

title

Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors. (English)

1 reference

17 March 2018

author name string

Andrew Alt

1

1 reference

17 March 2018

Annapurna Pendri

2

1 reference

17 March 2018

Robert L Bertekap

3

1 reference

17 March 2018

Guo Li

4

1 reference

17 March 2018

Yulia Benitex

5

1 reference

17 March 2018

Michelle Nophsker

6

1 reference

17 March 2018

Kristin L Rockwell

7

1 reference

17 March 2018

Neil T Burford

8

1 reference

17 March 2018

Chi Shing Sum

9

1 reference

17 March 2018

Jing Chen

10

1 reference

17 March 2018

John J Herbst

11

1 reference

17 March 2018

Meredith Ferrante

12

1 reference

17 March 2018

Adam Hendricson

13

1 reference

17 March 2018

Mary Ellen Cvijic

14

1 reference

17 March 2018

Ryan S Westphal

15

1 reference

17 March 2018

Jonathan O'Connell

16

1 reference

17 March 2018

Martyn Banks

17

1 reference

17 March 2018

Litao Zhang

18

1 reference

17 March 2018

Robert G Gentles

19

1 reference

17 March 2018

Susan Jenkins

20

1 reference

17 March 2018

James Loy

21

1 reference

17 March 2018

John E Macor

22

1 reference

17 March 2018

language of work or name

English

0 references

publication date

18 November 2015

1 reference

17 March 2018

Journal of Pharmacology and Experimental Therapeutics

published in

1 reference

17 March 2018

volume

356

1 reference

17 March 2018

issue

2

1 reference

17 March 2018

page(s)

293-304

1 reference

17 March 2018

Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies

cites work

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Strategies for the identification of allosteric modulators of G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Therapeutic opportunities for muscarinic receptors in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Muscarinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Muscarinic acetylcholine receptors as CNS drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Nicotinic acetylcholine receptors in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Development of allosteric modulators of GPCRs for treatment of CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

Emerging paradigms in GPCR allostery: implications for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FJPET.115.226910

21 January 2018

Identifiers

DOI

10.1124/JPET.115.226910

1 reference

17 March 2018

1 reference

17 March 2018